274 related articles for article (PubMed ID: 23936203)
1. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells.
Müller R; Misund K; Holien T; Bachke S; Gilljam KM; Våtsveen TK; Rø TB; Bellacchio E; Sundan A; Otterlei M
PLoS One; 2013; 8(7):e70430. PubMed ID: 23936203
[TBL] [Abstract][Full Text] [Related]
2. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling.
Olaisen C; Müller R; Nedal A; Otterlei M
Cell Signal; 2015 Jul; 27(7):1478-87. PubMed ID: 25797046
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel, widespread, and functionally important PCNA-binding motif.
Gilljam KM; Feyzi E; Aas PA; Sousa MM; Müller R; Vågbø CB; Catterall TC; Liabakk NB; Slupphaug G; Drabløs F; Krokan HE; Otterlei M
J Cell Biol; 2009 Sep; 186(5):645-54. PubMed ID: 19736315
[TBL] [Abstract][Full Text] [Related]
4. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
5. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Leiba M; Jakubikova J; Klippel S; Mitsiades CS; Hideshima T; Tai YT; Leiba A; Pines M; Richardson PG; Nagler A; Anderson KC
Br J Haematol; 2012 Jun; 157(6):718-31. PubMed ID: 22533681
[TBL] [Abstract][Full Text] [Related]
6. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D; Neri P; Velankar M; Podar K; Hideshima T; Fulciniti M; Tassone P; Raje N; Mitsiades C; Mitsiades N; Richardson P; Zawel L; Tran M; Munshi N; Anderson KC
Blood; 2007 Feb; 109(3):1220-7. PubMed ID: 17032924
[TBL] [Abstract][Full Text] [Related]
7. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.
Yu YL; Chou RH; Liang JH; Chang WJ; Su KJ; Tseng YJ; Huang WC; Wang SC; Hung MC
PLoS One; 2013; 8(4):e61362. PubMed ID: 23593472
[TBL] [Abstract][Full Text] [Related]
8. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Jakubikova J; Cervi D; Ooi M; Kim K; Nahar S; Klippel S; Cholujova D; Leiba M; Daley JF; Delmore J; Negri J; Blotta S; McMillin DW; Hideshima T; Richardson PG; Sedlak J; Anderson KC; Mitsiades CS
Haematologica; 2011 Aug; 96(8):1170-9. PubMed ID: 21712538
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
11. Structure of proliferating cell nuclear antigen (PCNA) bound to an APIM peptide reveals the universality of PCNA interaction.
Hara K; Uchida M; Tagata R; Yokoyama H; Ishikawa Y; Hishiki A; Hashimoto H
Acta Crystallogr F Struct Biol Commun; 2018 Apr; 74(Pt 4):214-221. PubMed ID: 29633969
[TBL] [Abstract][Full Text] [Related]
12. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.
Gravina GL; Colapietro A; Mancini A; Rossetti A; Martellucci S; Ventura L; Di Franco M; Marampon F; Mattei V; Biordi LA; Otterlei M; Festuccia C
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053455
[TBL] [Abstract][Full Text] [Related]
13. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
14. A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth.
Gu L; Smith S; Li C; Hickey RJ; Stark JM; Fields GB; Lang WH; Sandoval JA; Malkas LH
PLoS One; 2014; 9(4):e94773. PubMed ID: 24728180
[TBL] [Abstract][Full Text] [Related]
15. NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death.
Shemesh A; Kundu K; Peleg R; Yossef R; Kaplanov I; Ghosh S; Khrapunsky Y; Gershoni-Yahalom O; Rabinski T; Cerwenka A; Atlas R; Porgador A
Front Immunol; 2018; 9():1114. PubMed ID: 29875773
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
[TBL] [Abstract][Full Text] [Related]
17. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.
Alagpulinsa DA; Yaccoby S; Ayyadevara S; Shmookler Reis RJ
Cancer Biol Ther; 2015; 16(6):976-86. PubMed ID: 25996477
[TBL] [Abstract][Full Text] [Related]
18. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
20. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
